Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000009.xml
Download PDF
Am J Perinatol 2002; 19(1): 037-048
DOI: 10.1055/s-2002-20172
DOI: 10.1055/s-2002-20172
ORIGINAL ARTICLE
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662
Obstetric Implications of The Factor V Leiden Mutation: A Review
Further Information
Publication History
Publication Date:
18 February 2002 (online)
ABSTRACT
Factor V Leiden (FVL) is a newly discovered genetic mutation that impairs one of the body's naturally occurring anticoagulation systems. The result is resistance to activated protein C and a predisposition to thrombosis. FVL is the most common cause of primary and recurrent venous thromboembolism in the pregnant and nonpregnant state. The FVL gene is common in the general population and transmitted in an autosomal dominant fashion. When FVL is combined with the prothrombotic state of pregnancy, the result is an increased propensity to manifest a number of pregnancy complications. These include recurrent pregnancy loss and stillbirth, severe and early-onset preeclampsia, placental abruption and possibly, intrauterine growth restriction. It remains unknown whether thromboprophylaxis is effective in ameliorating these pregnancy complications. The current literature and management recommendations are highlighted in this article.
KEYWORD
Factor V Leiden - thrombophilia - pregnancy complications
REFERENCES
- 1 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci U S A . 1993; 90 1004-1008
- 2 Zoller B, Svensson P J, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest . 1994; 94 2521-2524
- 3 Bertina M R, Koeleman B P, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-67
- 4 Dahlback B, Stenflo J. The protein C anticoagulant system. In: Stamatoyannopoulos G, Niehuis AW, Majeurs PW, Varmus H, eds. The Molecular Basis
of Blood Diseases
Philadelphia: Saunders 1994: 599-624
MissingFormLabel
- 5 Girling J, deSwiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol . 1998; 10 135-144
- 6 Miles A M, Monga M. Factor V Leiden mutation: the most commonly inherited risk factor for venous thrombosis. Prim Care Update Ob/Gyn . 1999; 6 141-146
- 7 Cavenagh J D, Colvin B T. Guidelines for the management of thrombophilia. Postgrad Med J . 1996; 72 87-94
- 8 Gherman R B, Goodwin T M. Obstetric implications of activated protein C resistance and factor V Leiden mutation. Obstet Gynecol Surv . 2000; 55 117-122
- 9 Dahlback B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis . 1994; 24 139-151
- 10 Walker M C, Garner P R, Erin J K, Gail A R, Marchiano D R. Changes in activated protein C resistance in normal pregnancy. Am J Obstet Gynecol . 1997; 177 162-169
- 11 Lockwood C J. Heritable coagulopathies in pregnancy. Obstet Gynecol Surv . 1999; 54 754-765
- 12 Dahlback B. Resistance to activated protein C, the Arg 506 to Gln mutation in the factor V gene, and venous thrombosis. Thromb Haemosost . 1995; 73 739-742
- 13 Kupferminc M J, Eldor A, Steinman N. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med . 1999; 340 9-13
- 14 Ridker P M, Miletich J P, Hennekens C J, Buring J E. Ethnic distribution of factor V Leiden in 4,047 men and women. JAMA . 1997; 277 1305-1307
- 15 Dizon-Townson D, Nelson L M, Jang H, Varner M W, Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol . 1997; 176 883-886
- 16 Miletich J, Sherman L, Broze Jr G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med . 1987; 317 991-996
- 17 Hallak M, Senderowicz J, Cassel A. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol . 1997; 176 889-893
- 18 Grandone E, Margaglione M, Colaizzo D. Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20219A and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol . 1998; 179 1324-1328
- 19 Bonnar J, Green R, Norris L. Perinatal aspects of inherited thrombophilia. Semin Thromb Hemost . 1999; 25 481-485
- 20 Lindqvist P. Thrombotic risk during pregnancy: a population study. Obstet Gynecol . 1999; 94 595-599
- 21 Gerhardt A, Scharf R E, Beckmann M W. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med . 2000; 342 374-380
- 22 Sachs B P, Brown D AJ, Driscoll S G. Maternal mortality in Massachusetts: trends and prevention. New Engl J Med . 1987; 316 667-672
- 23 Hellgren M, Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol . 1995; 173 210-213
- 24 Svensson P J, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med . 1994; 330 517-522
- 25 Griffin J H, Evatt B, Widerman C, Fernandez J A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood . 1993; 82 1989-1993
- 26 Koster T, Rosendaal F R, de Ronde H, Briet E, Vandenbroucke J P, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet . 1994; 342 1503-1506
- 27 Bokarewa M I, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol . 1996; 92 473-478
- 28 Koeleman B P, Reitsma P H, Allaart C F, Bertina R M. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood . 1994; 84 1031-1035
- 29 Rotmensch S, Liberati M, Mittlemann M, Ben-Rafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol . 1997; 177 170-173
- 30 Arias F, Romero R, Joist H, Kraus F T. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions of the placenta. J Matern Fetal Med . 1998; 7 277-286
- 31 Rai R S, Regan L, Hadley E. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol . 1996; 92 489-490
- 32 Brenner B, Mandel H, Lanir N. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol . 1997; 97 551-554
- 33 Grandone E, Margaglione M, Colaizzo S. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost . 1997; 77 822-824
- 34 Meinardi J R, Middeldorp S, de Kam J P. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med . 1999; 130 736-739
- 35 Nemes L, Pajor A, Cegled A. Comparison of the risk of fetal loss between homozygous and heterozygous patients with factor V Leiden mutation. Thromb Haemost . 1999; 534(suppl) 534-536
- 36 Preston F E, Rosendaal F R, Walker I D. Increased fetal loss in women with heritable thrombophilia. Lancet . 1996; 348 913-916
- 37 Rai R S, Regan L, Chitolie A. Placental thrombosis and second trimester miscarriage associated with activated protein C resistance. Br J Obstet Gynecol . 1996; 103 842-844
- 38 Dizon-Towson D S, Meline L, Nelson L M. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction. Am J Obstet Gynecol . 1997; 177 402-405
- 39 Weiner-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence with abruptio placentae. Am J Obstet Gynecol . 1998; 179 1565-1567
- 40 Grisaru D, Fait G, Eldor A. Activated protein C resistance and pregnancy complications. Am J Obstet Gynecol . 1996; 174 801-802
- 41 Dizon-Townson D S, Nelson L M, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol . 1996; 175 902-905
- 42 Lindoff C, Ingemarsson I, Martinsson G, Segelmark M, Thysell H, Astedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol . 1997; 176 457-460
- 43 Grandone E, Margaglione M, Colaizzo D. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Haemost . 1997; 77 1052-1054
- 44 Hastings S, Knowlton J, Nelson L. Obstetrical and medical complications in women with the factor V Leiden mutation. Am J Obstet Gynecol . 1998; 178 S104
- 45 van Pampus G M, Dekker G A, Wolf H. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol . 1999; 180 1146-1150
- 46 Rigo J, Nagy B, Fintor L. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of Factor V Leiden mutation and 5,10 methylenetetradydrofolate reductase. Hypert Preg . 2000; 19 163-172
- 47 Dekker G A, de Vries I J, Doelitzsch P M. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol . 1995; 173 1042-1048
- 48 Krauss T, Augustin H G, Osmers R. Activated protein C resistance and Factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol . 1998; 92 457-460
- 49 Erhardt E, Stankovics J, Molnar D, Adamovich K, Melegh G. High prevalence of Factor V Leiden mutation in mothers of premature neonates. Biol Neonate . 2000; 78 145-146
- 50 Wisotzkey J D, Bayliss P, Rutherford E, Bell T. Placental genotyping of the factor V Leiden, Prothrombin 20210A and the methylenetetrahydrofolate reductase (MTHFR) C677T alleles in IUGR pregnancies. Thromb Haemost . 1999; 81 844-845
- 51 SOGC Clinical Practice Guidelines. Prevention and treatment of venous thromboembolism in obstetrics. September, 2000;
- 52 Barbour L A. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin . 1997; 24 499-521
- 53 Ginsberg J S, Hirsh J. Fifth ACCP Consensus Conference on Antithrombotic therapy. Chest . 1998; 114 524-530
- 54 Lensing A W, Prins M H, Davidson B L. Treatment of deep venous thrombosis with low molecular weight heparins: a meta-analysis. Arch Intern Med . 1995; 155 601-607
- 55 ACOG Practice Bulletin. Thromboembolism in pregnancy. Number 19, August, 2000
MissingFormLabel
- 56 Rao A K, Kaplan R, Sheth S. Inherited thrombophilic states. Semin Thromb Hemost . 1998; 24 (suppl 1) 3-12
- 57 Heilmann L, Schneider D M, von Tempelhoff G. Antithrombotic therapy in high-risk pregnancy. Hematol Oncol Clin North Am . 2000; 13 1133-1150
- 58 Brill-Edwards P, Ginsberg J S, Gent M. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med . 2000; 343 1439-1444
- 59 Nelson-Piercy C, Letsky E A, de Swiet M. Low molecular weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women of high risk. Am J Obstet Gynecol . 1997; 176 1062-1068
- 60 Sanson B J, Lensing A WA, Prins M H. Safety of low molecular weight heparin in pregnancy: a systematic review. Thromb Haemost . 1999; 81 668-672
- 61 Riyazi N. Low-molecular weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol . 1998; 80 49-54
- 62 Preston F E, Rosendaal F R, Walker I D. Thromboprophylaxis in pregnancy reduces fetal loss in women with heritable thrombophilia: a prospective EPCOT study. Thromb Haemost . 1999; 227 (suppl 1) 227-231
- 63 Hoffmann R, Younis J, Blumenfeld Z. Enoxoparin is effective in prevention of pregnancy loss in women with thrombophilia. Thromb Haemost . 1999; 531(suppl) 531-534
- 64 De Stefano V, Mastrangelo S, Paciaroni K. Thrombotic risk during pregnancy and puerperium in women with APC resistance: effective subcutaneous heparin prophylaxis in pregnant patients. Thromb Haemost . 1995; 74 793-794